Peripheral Delta Opioid Receptors Mediate Formoterol Anti-allodynic Effect in a Mouse Model of Neuropathic Pain.
beta adrenergic receptor
beta-mimetics
cuff model
delta opioid receptor
mechanical allodynia
peripheral nerve injury
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
08
2019
accepted:
17
12
2019
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
Neuropathic pain is a challenging condition for which current therapies often remain unsatisfactory. Chronic administration of β2 adrenergic agonists, including formoterol currently used to treat asthma and chronic obstructive pulmonary disease, alleviates mechanical allodynia in the sciatic nerve cuff model of neuropathic pain. The limited clinical data currently available also suggest that formoterol would be a suitable candidate for drug repurposing. The antiallodynic action of β2 adrenergic agonists is known to require activation of the delta-opioid (DOP) receptor but better knowledge of the molecular mechanisms involved is necessary. Using a mouse line in which DOP receptors were selectively ablated in neurons expressing Nav1.8 sodium channels (DOP cKO), we showed that these DOP peripheral receptors were necessary for the antiallodynic action of the β2 adrenergic agonist formoterol in the cuff model. Using a knock-in mouse line expressing a fluorescent version of the DOP receptor fused with the enhanced green fluorescent protein (DOPeGFP), we established in a previous study, that mechanical allodynia is associated with a smaller percentage of DOPeGFP positive small peptidergic sensory neurons in dorsal root ganglia (DRG), with a reduced density of DOPeGFP positive free nerve endings in the skin and with increased DOPeGFP expression at the cell surface. Here, we showed that the density of DOPeGFP positive free nerve endings in the skin is partially restored and no increase in DOPeGFP translocation to the plasma membrane is observed in mice in which mechanical pain is alleviated upon chronic oral administration of formoterol. This study, therefore, extends our previous results by confirming that changes in the mechanical threshold are associated with changes in peripheral DOP profile. It also highlights the common impact on DOP receptors between serotonin noradrenaline reuptake inhibitors such as duloxetine and the β2 mimetic formoterol.
Identifiants
pubmed: 32116538
doi: 10.3389/fnmol.2019.00324
pmc: PMC7033630
doi:
Types de publication
Journal Article
Langues
eng
Pagination
324Informations de copyright
Copyright © 2020 Ceredig, Pierre, Doridot, Alduntzin, Hener, Salvat, Yalcin, Gaveriaux-Ruff, Barrot and Massotte.
Références
Eur J Neurosci. 2018 Sep;48(5):2231-2246
pubmed: 30059180
Neuroscience. 2016 Dec 3;338:183-206
pubmed: 27401055
Br J Pharmacol. 2015 Jan;172(2):403-19
pubmed: 24665909
Brain Res. 2014 Feb 10;1546:18-26
pubmed: 24361988
Neuron. 2012 Feb 23;73(4):638-52
pubmed: 22365541
Eur J Neurosci. 2006 Feb;23(3):830-4
pubmed: 16487163
PLoS One. 2014 Aug 08;9(8):e104420
pubmed: 25105291
Neuroscience. 2016 Jan 28;313:46-56
pubmed: 26480813
Biol Psychiatry. 2011 Nov 15;70(10):946-53
pubmed: 21890110
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9691-6
pubmed: 16766653
Exp Neurol. 2010 Jan;221(1):115-21
pubmed: 19840789
J Pharmacol Exp Ther. 2012 Sep;342(3):799-807
pubmed: 22700431
Pain. 2011 Jun;152(6):1238-48
pubmed: 21295407
Ann Neurol. 2009 Feb;65(2):218-25
pubmed: 19259968
J Neurosci. 2018 Nov 14;38(46):9934-9954
pubmed: 30249798
J Vis Exp. 2014 Jul 16;(89):
pubmed: 25078668
Eur J Pain. 2008 Jul;12(5):591-9
pubmed: 18006342
J Neuroinflammation. 2016 Oct 7;13(1):262
pubmed: 27717401
Brain Res. 2015 Jul 21;1614:105-11
pubmed: 25911583
Br J Pharmacol. 2009 Dec;158(7):1683-94
pubmed: 19912227
Neurobiol Dis. 2013 Dec;60:39-50
pubmed: 23978467
J Invest Dermatol. 2011 Mar;131(3):613-22
pubmed: 21191404
Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981
pubmed: 30587953
Mol Pain. 2015 Sep 17;11:59
pubmed: 26376854
BMC Res Notes. 2019 Jul 15;12(1):413
pubmed: 31307541
Mol Pain. 2016 Sep 02;12:
pubmed: 27590071
Biol Psychiatry. 2008 Mar 15;63(6):633-6
pubmed: 17693391
Mol Pain. 2016 Mar 29;12:
pubmed: 27030724
J Neurosci. 2008 Jun 25;28(26):6652-8
pubmed: 18579738
J Neuroinflammation. 2010 Apr 16;7:27
pubmed: 20398373
Eur J Pain. 2015 Nov;19(10):1428-36
pubmed: 25766791
Eur J Pain. 2008 Nov;12(8):1008-17
pubmed: 18331804
Eur J Neurol. 2005 Oct;12(10):747-58
pubmed: 16190912
Brain Behav Immun. 2016 Oct;57:227-242
pubmed: 27139929
Eur J Neurosci. 2004 Jul;20(1):92-100
pubmed: 15245482
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):343-8
pubmed: 11134510